Fusion Pharmaceuticals Inc. (FUSN): Price and Financial Metrics


Fusion Pharmaceuticals Inc. (FUSN): $8.56

-0.30 (-3.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

FUSN Stock Price Chart Interactive Chart >

Price chart for FUSN

FUSN Price/Volume Stats

Current price $8.56 52-week high $13.89
Prev. close $8.86 52-week low $6.61
Day low $8.49 Volume 42,644
Day high $8.81 Avg. volume 56,092
50-day MA $8.50 Dividend yield N/A
200-day MA $9.81 Market Cap 368.25M

Fusion Pharmaceuticals Inc. (FUSN) Company Bio


Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant and is headquartered in Hamilton, Canada.


FUSN Latest News Stream


Event/Time News Detail
Loading, please wait...

FUSN Latest Social Stream


Loading social stream, please wait...

View Full FUSN Social Stream

Latest FUSN News From Around the Web

Below are the latest news stories about Fusion Pharmaceuticals Inc that investors may wish to consider to help them evaluate FUSN as an investment opportunity.

Fusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Business Development

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Eric S. Hoffman, Ph.D. as senior vice president, business development.

Yahoo | September 21, 2021

Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming virtual investor conferences.

Yahoo | September 2, 2021

We Think Fusion Pharmaceuticals (NASDAQ:FUSN) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | August 23, 2021

Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production

Fusion and TRIUMF to collaborate to produce actinium based on technology developed by TRIUMF HAMILTON, ON and BOSTON and VANCOUVER, BC, Aug. 12, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation

PR Newswire | August 12, 2021

Fusion Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Update

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the second quarter ended June 30, 2021 and provided an update on clinical and corporate developments.

Yahoo | August 10, 2021

Read More 'FUSN' Stories Here

FUSN Price Returns

1-mo 3.01%
3-mo 6.20%
6-mo -15.42%
1-year -30.24%
3-year N/A
5-year N/A
YTD -27.15%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.1022 seconds.